Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
Brigham and Women's Hospital, Boston, Massachusetts, United States
Children's Hospital Boston, Boston, Massachusetts, United States
University Hospital of Tomas Bati, Department of Neonatology, Zlin, Czech Republic
Tampere University Hospita, NICU, Tampere, Finland
Erasmus MC - Sophia, Department of Neonatology, Rotterdam, Netherlands
Research Site, Uppsala, Sweden
Allied Research International - Cetero Research, Mississauga, Ontario, Canada
University of Regensburg, Regensburg, Germany
The Hebrew University-Hadassah School of Dental Medicine, Department of Oral Medicine, Jerusalem, Israel
China Medical University, Taichung, Taiwan, China
University Hospital Basel, Basel, Switzerland
Department of Respiratory Medicine, Kuopio University Hospital, Kuopio, Finland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.